References

Contemporary management of acute myeloid leukemia: a review

10.1001/jamaoncol.2024.2662 · 2024 · External reference

Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets

10.1182/blood.2022018092 · 2023 · External reference

Prediction of acute myeloid leukaemia risk in healthy individuals

10.1038/s41586-018-0317-6 · 2018 · External reference

Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance

10.1016/j.stem.2022.12.003 · 2023 · External reference

Catch me if you can: how AML and its niche escape immunotherapy

10.1038/s41375-021-01350-x · 2022 · External reference

Single-cell genomics in AML: extending the frontiers of AML research

10.1182/blood.2021014670 · 2023 · External reference

A membrane-associated MHC-I inhibitory axis for cancer immune evasion

10.1016/j.cell.2023.07.016 · 2023 · External reference

Coordinated immune networks in leukemia microenvironments distinguish response to cellular therapy

10.1126/sciimmunol.adr0782 · 2025 · External reference

The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF-kB signaling

10.1182/blood.2024028199 · 2025 · External reference

An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia

2023 · External reference

A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia

10.1016/j.cell.2019.04.040 · 2019 · External reference

Mapping dysfunction of the bone marrow stroma in leukaemia

10.1038/s41568-019-0165-1 · 2019 · External reference

Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling

10.1038/s41375-022-01798-5 · 2023 · External reference

Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia

10.1038/s41467-023-44270-3 · 2024 · External reference

Aspartate signalling drives lung metastasis via alternative translation

10.1038/s41586-024-08335-7 · 2025 · External reference

Bone marrow mesenchymal stromal cell-derived periostin promotes B-ALL progression by modulating CCL2 in leukemia cells

10.1016/j.celrep.2019.01.034 · 2019 · External reference

IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy

10.1016/j.xcrm.2024.101826 · 2024 · External reference

Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML

10.1126/sciadv.adw4871 · 2025 · External reference

TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice

2023 · External reference

FGF-based drug discovery: advances and challenges

10.1038/s41573-024-01125-w · 2025 · External reference

Naive pluripotent stem cell-based models capture FGF-dependent human hypoblast lineage specification

10.1016/j.stem.2024.05.003 · 2024 · External reference

FGF-23 from erythroblasts promotes hematopoietic progenitor mobilization

10.1182/blood.2020007172 · 2021 · External reference

FGF18 alleviates hepatic ischemia-reperfusion injury via the USP16-mediated KEAP1/Nrf2 signaling pathway in male mice

10.1038/s41467-023-41800-x · 2023 · External reference

Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice

10.1038/s41467-023-36895-1 · 2023 · External reference

Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis

10.1074/jbc.m410148200 · 2005 · External reference

Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity

10.1126/sciimmunol.abo3420 · 2022 · External reference

IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia

10.1126/scitranslmed.aax5104 · 2020 · External reference

Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy

10.1038/s41467-021-26407-4 · 2021 · External reference

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia

10.1182/blood.2024028239 · 2025 · External reference

The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1β-mediated AML progression

10.1182/blood.2023022079 · 2024 · External reference

Escape from T-cell-targeting immunotherapies in acute myeloid leukemia

10.1182/blood.2023019961 · 2024 · External reference

Recent advances in immune-based therapies for acute myeloid leukemia

10.1158/2643-3230.bcd-23-0202 · 2024 · External reference

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

10.1038/s41467-021-26282-z · 2021 · External reference

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade

10.1038/s41375-019-0639-x · 2020 · External reference

Aberrant notch signaling in the bone marrow microenvironment of acute lymphoid leukemia suppresses osteoblast-mediated support of hematopoietic niche function

10.1158/0008-5472.can-15-2092 · 2016 · External reference

Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies

10.1158/2159-8290.cd-22-0199 · 2023 · External reference

Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis

10.1016/j.stem.2020.11.004 · 2021 · External reference

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

10.1172/jci170953 · 2024 · External reference

Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche

10.1038/s41375-024-02136-7 · 2024 · External reference

B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/β response in bone marrow-derived mesenchymal stroma

10.3324/haematol.2023.283494 · 2024 · External reference

Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias

10.1126/scitranslmed.adr1471 · 2025 · External reference

Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset

10.1182/bloodadvances.2021005938 · 2022 · External reference

Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance

10.1038/s41408-021-00426-2 · 2021 · External reference

Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-β1-driven macrophage polarization in myeloid leukemias

2025 · External reference

Loss of bisecting GlcNAcylation on MCAM of bone marrow stoma determined pro-tumoral niche in MDS/AML

10.1038/s41375-022-01748-1 · 2023 · External reference

FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p

10.1038/s41388-018-0430-x · 2019 · External reference

Fibroblast growth factor signalling in osteoarthritis and cartilage repair

10.1038/s41584-020-0469-2 · 2020 · External reference

Intercellular communication between hepatic stellate cells and myofibroblasts mediated by osteopontin and FGF18 promotes liver fibrosis

10.1016/j.isci.2025.112932 · 2025 · External reference

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies

10.1002/cac2.12602 · 2024 · External reference

FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation

10.1158/0008-5472.can-23-1065 · 2023 · External reference

FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models

10.1172/jci173757 · 2025 · External reference

Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience

10.1158/1078-0432.ccr-23-1283 · 2023 · External reference

Phospholipase D1 acts through Akt/TopBP1 and RB1 to regulate the E2F1-dependent apoptotic program in cancer cells

10.1158/0008-5472.can-15-3032 · 2017 · External reference

A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity

10.1038/s41590-025-02231-6 · 2025 · External reference

Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response

10.1126/sciadv.adt4258 · 2025 · External reference

Immune checkpoints regulate acute myeloid leukemia stem cells

10.1038/s41375-025-02566-x · 2025 · External reference

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

10.1172/jci.insight.120974 · 2018 · External reference

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients

10.1038/s41408-018-0069-4 · 2018 · External reference

Expression patterns of immune checkpoints in acute myeloid leukemia

10.1186/s13045-020-00853-x · 2020 · External reference